Cardiome Pharma Corp. (NASDAQ:CRME) Closing price $2.15
On Wednesday, Cardiome announced an arrangement with AOP Orphan Pharmaceuticals, headquartered in Vienna, to commercialize Brinavess (vernakalant intravenous) in certain European markets. The Austrian firm will support Cardiome in gaining product registrations necessary for the marketing and sale of the drug in the AOP Orphan countries, and it will actively request that customers promote the product. Through the terms, AOP Orphan has consented to specific yearly commercial goals for Brinavess. Financials of the transaction were not disclosed.